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Nuclear imaging methods for the
prediction of postoperative morbidity and
mortality in patients undergoing localized,
liver-directed treatments: a systematic
review
Caroline Espersen1* , Lise Borgwardt1, Peter Nørgaard Larsen2, Trine Borup Andersen3, Louise Stenholt4 and
Lars Jelstrup Petersen5,3
Abstract
Background: Several nuclear imaging methods may predict postoperative liver function and outcome, but none
has achieved recommendations in clinical guidelines. The purpose of this systematic review was to summarize the
existing knowledge on this topic.
Methods: MEDLINE and Web of Science were searched for studies investigating nuclear medicine imaging
methods for the prediction of postoperative liver function in patients undergoing localized, liver-directed
treatments. The postoperative endpoints were clinical outcome (morbidity and mortality) as well as measures of
postoperative liver function, e.g., liver function assessed by biochemical tests or nuclear imaging.
Results: A total of 1352 references were identified, of which 82 fulfilled the eligibility criteria and were included in
the review. Most studies (n = 63) were retrospective studies. The vast majority of studies assessed [99mTc]Tc-
galactosyl serum albumin (GSA) (n = 57) and [99mTc]Tc-mebrofenin (n = 19). Liver resection was entirely or partly
major (involved at least three segments) in 78 reports. There were notable variations in the research methodology,
e.g., image acquisition, imaging variables, and endpoints. Thirty-seven studies reported on postoperative mortality,
of which most reported descriptive data at the patient level. Of the four reports that performed multivariate
analyses, two showed significant predictive results of isotope-based preoperative tests. Fifty-two papers presented
data on postoperative liver failure. Multivariate predictive analyses were performed in eighteen trials, of which
fifteen showed the significant value of nuclear medicine tests.
Conclusion: There is sparse evidence supporting the significant value of nuclear medicine imaging methods in
predicting postoperative mortality. In contrast, a notable number of trials showed a significant prediction of liver
failure in multivariate analyses. The research methodology was heterogeneous and exploratory in most trials.
Documentation of nuclear medicine tests in this setting awaits the results of properly designed, prospective trials
with the standardization of both the nuclear medicine test and endpoints.
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Background
Despite the advancement and improvement of surgical
techniques and perioperative management over recent
years [1], major liver resection still bears the risk of in-
ducing postoperative liver failure (LF) or other major
liver-related complications, especially in patients with
underlying parenchymal liver disease [2, 3]. LF is a ser-
ious complication following liver resection and the major
cause of postoperative mortality and morbidity [4, 5].
However, liver resection remains the best curative
method for treating colorectal liver metastases [6, 7] and
primary hepatobiliary cancers [7]. Insufficient remnant
liver function is an important factor contributing to a
poor postoperative outcome [6]. Therefore, any proced-
ure with the purpose of removing large amounts of dis-
eased liver tissue should include a pre-procedural risk
assessment by estimating the future liver remnant (FLR)
function to avoid post-procedure LF, mortality, or other
liver-related complications.
Both computed tomography (CT) and biochemical
liver function tests have been employed in the preopera-
tive assessment by measuring the volume of the FLR and
the global liver function, respectively [8]. CT is presently
the gold standard for the preoperative evaluation of the
FLR [9]. Using CT volumetry as an indirect assessment
of FLR function assumes that the liver function is homo-
genously distributed. However, as patients often present
with compromised livers with heterogeneously distrib-
uted liver function, this assumption is not always true.
Therefore, estimating the function of the FLR directly
may be more reliable in predicting the real postoperative
remnant liver function rather than estimating the vol-
ume or global liver function [8, 10, 11].
With the use of specific nuclear imaging techniques, it
is possible to evaluate the function of the FLR directly.
Presently, there are no guidelines or definite, widely ac-
cepted recommendations on liver function assessment
with nuclear imaging methods prior to a procedure with
the purpose of removing or destroying diseased, local-
ized liver parenchyma. Therefore, it would be of great
clinical value to establish a reliable, noninvasive method
with specific guidelines and cut-off values for the pre-
operative assessment of postoperative risk in patients
undergoing liver resection.
The purpose of this systematic review was to investi-
gate the clinical documentation of preprocedural nuclear
imaging methods to predict postprocedural clinical out-
comes after local intervention in the liver, including the
prediction of LF and death.
Materials and methods
Literature search strategy
The literature search was performed by a trained re-
search librarian (LS) using two bibliographic databases,
MEDLINE (Ovid) and Web of Science Core Collection
(Clarivate Analytics). The search period spanned from
the start date of each database until May 27, 2020. Due
to the extensive amount of work preparing this review,
the original search was outdated, and a new search was
performed (as of May 27, 2020) in order to ensure that
no relevant studies meeting the criteria for inclusion
were left out. The literature search was customized for
each bibliographic database and set up to match the pre-
defined PICOS criteria (patient, intervention, compari-
son, outcome, study design) (Supplementary file 1). In
brief, we searched for original papers where a nuclear
medicine imaging examination was performed prior to
any intervention for localized liver disease, and the re-
sults of the imaging assessment were compared to a clin-
ical outcome. Using both controlled thesaurus terms and
natural language terms to include synonyms, the search
terms included descriptions of the underlying liver con-
dition, the liver intervention, and the liver nuclear im-
aging technique (see Supplementary file 2 for the exact
search profiles). All the identified references were run
through a reference managing software tool (EndNote
X9, Clarivate Analytics, Philadelphia, USA) to identify
duplicate studies. The unique references were entered
into a systematic review management system (Covi-
dence, Veritas Health Innovation, Melbourne, Australia),
which was used for title/abstract and full-text screening
of the studies. There is no public protocol registration
for this systematic review. The systematic review was
conducted in full accordance with the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [12].
Eligibility criteria
The eligibility criteria were as follows. (1) The included
patients had to undergo local treatment for focal or
multifocal liver disease with an intent to eliminate the
diseased liver tissue, irrespective of the underlying cause
of disease. (2) The interventions included both liver in-
terventions and preprocedural imaging interventions.
The liver interventions included but were not limited to
surgery, radiotherapy, cryotherapy, percutaneous ethanol
injection, percutaneous microwave coagulation therapy,
radiofrequency ablation, or transcatheter arterial che-
moembolization. The imaging interventions involved the
preprocedural assessment of liver function with a nu-
clear medicine imaging method. (3) There was no re-
quirement of any comparator. (4) The outcome had to
be correlated to the preprocedural nuclear imaging tech-
nique and included reporting of postoperative mortality,
LF, postoperative complications, and/or postoperative
liver function tests (e.g., biochemical tests or nuclear im-
aging techniques). (5) Any study design with a minimum
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of five patients per study was considered (Supple-
mentary file 1).
Study selection
Two investigators independently performed the review
of the studies. Initially, the original studies retrieved
from the literature search were reviewed for eligibility
based on reading the titles and abstracts. Only if the two
investigators agreed upon exclusion at this level, the
paper was discarded. The full texts of all the remaining
papers were subsequently read. The systematic review
included studies meeting all eligibility criteria as judged
by both investigators.
Data extraction
The following data were extracted: country (affiliation of
the first author), year of publication, patient enrolment
(prospective/retrospective), patient selection (consecutive/
nonconsecutive), number of included patients undergoing
liver intervention and nuclear imaging who were followed
for outcome, type of liver intervention, nuclear medicine
imaging technique, and outcome reporting. The number
of included patients only encompasses the patients under-
going a preprocedural nuclear imaging examination and
an intervention with the purpose of removing diseased
liver tissue. Patient enrolment was characterized as pro-
spective if the word “prospective” was used, the termin-
ology was clear, it was described as an interventional
design, informed consent was obtained individually before
participation in the study, and/or the study partly com-
prised healthy volunteers (even without providing infor-
mation about informed consent or ethical approval).
Patient selection was classified as consecutive if the word
“consecutive” was used or it was clear that all patients
meeting certain eligibility criteria in a well-defined time
period were included in the study. The surgical procedure
was characterized as a major or minor surgery according
to the Couinaud criteria (resection ≥ 3 liver segments vs.
1–2 segments) [13].
It was recorded whether the study reported outcome
data categorized as mortality, LF, other clinical morbid-
ity, or liver function tests (yes/no option) if they corre-
lated the preoperative nuclear medicine test to the
postoperative outcome. Due to the large number of pa-
pers reporting high-level outcomes (mortality and LF),
detailed data extraction was performed for these two
categories only. The outcome data were extracted pro-
vided the study included data for a preprocedural nu-
clear imaging examination and postprocedural mortality
or LF. If data on mortality and LF were reported inde-
pendently, the data were extracted for each of these out-
comes separately. If a study analyzed a postprocedural
composite endpoint, e.g., overall complications including
mortality or LF, the mortality and/or LF data were
extracted if possible and reported separately if preproce-
dural nuclear imaging data were reported separately for
those deceased and for those who developed LF. Other-
wise, the outcome was shown as a composite outcome
and reported in either the mortality or liver failure table
or both depending on the number of events for each out-
come. The outcome data were reported in the mortality
table if all patients with LF died or in the LF table if the
majority of these patients developed LF, of which a few
died. If the definition of LF included death without other
cause, mortality events due to LF were only reported in
the LF outcome table. Last, if the paper reported on LF-
related complications or signs of postoperative LF, it was
included in the liver failure outcome table.
The following data were also extracted: (1) the defini-
tions of mortality (e.g., all-cause mortality or in-hospital
mortality) and LF; (2) the outcome event rate; (3)
whether a study analyzed a predefined cut-off value of
the nuclear imaging examination in a prospective setting
or if the study established a post hoc cut-off value based
on the observed results; (4) the diagnostic characteristics
of the cut-off value as well as comparisons between the
uptake values of the nuclear imaging examination in pa-
tients with or without an outcome; and eventually (5)
available data regarding the predictive value of the nu-
clear imaging examination and outcome based on uni-
variate or multivariate analyses in logistic or cox
regression models.
Statistics
Descriptive statistics comprised the calculation of the
median and range. No analytical statistics were used.
Ethics
In compliance with national legislation, no ethical ap-
proval or informed consent was obtained for this sys-
tematic review, as it only contains data from previously
published articles and no individual data.
Results
Literature search and review
A total of 1344 studies were retrieved from the literature
search, and eight studies were retrieved from other
sources (Fig. 1). After the removal of duplicates, 1119
studies were screened. Based on the title and abstract
screening, 933 studies were excluded, leaving 186 studies
for full-text screening, of which 82 eligible studies were
included in the systematic review.
Study demographics
The majority of the included studies investigated the use
of [99mTc]Tc-GSA (57 studies), and the majority of those
trials originated from Japan (56 studies) (Table 1). Nine-
teen studies investigated the use of [99mTc]Tc-mebrofenin.
Espersen et al. EJNMMI Research          (2020) 10:101 Page 3 of 22
The remaining six studies employed the following tracers:
[18F]FDG, [99mTc]Tc-Sn colloid, [99mTc]Tc-colloid,
[99mTc]Tc-PMT, L-[methyl-11C]-methionine, and
[198Au]Au colloid + [99mTc]Tc-Sn colloid. The vast major-
ity of the studies were retrospective, and only nineteen pa-
pers were prospective. Forty-seven studies explicitly
defined consecutive recruitment of patients. The year of
publication spanned four decades from 1989 to 2020 (me-
dian 2010). The median number of included patients
undergoing both a preprocedural nuclear medicine im-
aging examination and a procedure with the purpose of
eliminating diseased liver tissue was 67 (5 to 625 patients).
Some studies investigated major surgery exclusively in-
cluding some studies investigating associating liver parti-
tion and portal vein ligation for staged hepatectomy
(ALPPS) [21, 69, 72, 80, 82, 83]. The majority of the stud-
ies investigated both major and minor surgery. Four
studies also included non-operative interventions such as
radiofrequency ablation, transarterial embolization or che-
moembolization, percutaneous ethanol injection, or
microwave coagulation therapy [31, 52, 75, 87]. The vast
majority of trials reported on postoperative LF or mortal-
ity. Sixteen papers reported solely on postprocedural mor-
bidity and/or nonclinical outcome (liver function assessed
by imaging or laboratory/biochemical tests) (Table 1), and
an additional 48 studies reported on such data along with
data on LF and/or mortality.
Prediction of postoperative mortality
Thirty-seven studies correlated the findings from a pre-
operative nuclear medicine imaging investigation to
postoperative mortality (Table 2). All of the trials in-
volved major intervention (entirely or partly) except for
one study in which the extent of liver resection was not
Fig. 1 Consort flow diagram of the article selection process
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Table 2 Overview of trials reporting on the correlation between a preoperative nuclear imaging examination and postoperative
mortality
Author Mortality
defined
Mortality
event
rate
Preset
cut off
studied
Post hoc
cut-off value
established
Only
descriptive
analysis
Mortality vs
no mortality
comparison
Key diagnostic
characteristics
reported
Cut-off value
predictive in
univariate regression
analysis
Cut-off value
predictive in
multivariate
regression analysis
Das et al.
[23]
Yes 4% No Yes Yes NR NR NR NR
Dinant
et al. [24]
No 11% No Yes No Yes Yes Yes No
Cieslak
et al. [16]
Yes 7% Yes No Yes NR NR NR NR
Chapelle
et al. [19]
Yes 6% No Yes1 Yes NR NR NR NR
Chapelle
et al. [20]
Yes 0%2 Yes1 No Yes NR NR NR NR
Chiba et al.
[18]
No3 2% Yes1 No Yes NR NR NR NR
Franken
et al. [25]
Yes 13%4 Yes No Yes5 NR NR NR NR
Fujioka
et al. ≠ [26]
No 7% No Yes Yes NR NR NR NR
Guiu et al.
[27]
Yes 0% Yes No Yes NR NR NR NR
Hayashi
et al. [28]
Yes 6% Yes No No NR NR Yes NR
Hino et al.
[29]
No 6% No Yes6 Yes NR NR NR NR
Kaibori
et al. [34]
No 2% No Yes1 Yes NR NR NR NR
Kim et al. ≠
[39]
No 10% No Yes No Yes NR NR Yes
Kwon et al.
[42]
No 2% No Yes Yes NR NR NR NR
Kwon et al.
[43]
No 2% No Yes Yes NR NR NR NR
Kwon et al.
[44]
No 3% No Yes Yes NR NR NR NR
Kwon et al.
[45]
No 1% No Yes Yes NR NR NR NR
Kwon et al.
≠ [46]
No 1% No Yes6 Yes NR NR NR NR
Namieno
et al. [53]
No 0% Yes No Yes NR NR NR NR
Nishikawa
et al. [60]
Yes 42% No Yes No Yes7 NR Yes Yes
Nishiyama
et al. [61]
No 10% No Yes No NR Yes NR NR
Okabayashi
et al. [63]
Yes 1% Yes No Yes NR NR NR NR
Olthof et al.
[65]
Yes 18% Yes8 Yes8 No NR Yes8 NR NR
Otsuki et al.
[66]
No 27% No Yes No Yes NR NR NR
Rassam
et al. [67]
Yes 11% Yes No No Yes NR NR NR
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described [35]. Postoperative mortality was defined ex-
plicitly up front in fifteen trials only. The mortality defi-
nitions varied though most used 90-day postoperative
mortality. The mortality rate varied considerably (0 to
52%). There were major technical methodological varia-
tions across the studies. For example, among the 22
studies investigating [99mTc]Tc-GSA, there were fifteen
different ways of calculating the preoperative liver up-
take of the tracer (data not shown).
Most studies retrospectively reported the nuclear
medicine investigation results among patients with a
fatal outcome versus those with a non-fatal outcome or
described the proportion of patients with a fatal out-
come below or above a defined cut-off value. A minority
of the studies provided clinically relevant prognostic in-
formation in the form of preoperative nuclear medicine
results in patients with fatal versus nonfatal outcomes,
analyzed diagnostic test accuracy characteristics, or
assessed predictive values in univariate and multivariate
analyses (Table 2). Thirty-three studies described a pre-
operative cut-off value for the prediction of postopera-
tive mortality or mortality as part of a composite
outcome. Twelve of these studies used a predetermined
cut-off value. Five papers (of which two reports had
Table 2 Overview of trials reporting on the correlation between a preoperative nuclear imaging examination and postoperative
mortality (Continued)
Author Mortality
defined
Mortality
event
rate
Preset
cut off
studied
Post hoc
cut-off value
established
Only
descriptive
analysis
Mortality vs
no mortality
comparison
Key diagnostic
characteristics
reported
Cut-off value
predictive in
univariate regression
analysis
Cut-off value
predictive in
multivariate
regression analysis
Satoh et al.
≠ [68]
No 4% No Yes6 No NR Yes6 NR NR
Serenari
et al. [69]
Yes 5% No Yes9 Yes NR NR NR NR
Sumiyoshi
et al. [75]
Yes 0% Yes No Yes NR NR NR NR
Takeuchi
et al. ≠ [76]
No 8% No No No Yes6 NR NR NR
Tanabe
et al. [77]
No 52% No Yes No Yes NR NR NR
Tanaka
et al. [79]
No 2%10 Yes No Yes NR NR NR NR
Truant et al.
[82]
No 20% No No Yes NR NR NR NR
Truant et al.
[83]
No 14%11 No No Yes NR NR NR NR
Yamao
et al. [87]
Yes 25%12 No No No NR NR No NR
Yano et al.
[89]
Yes 18%13 No Yes No Yes7 NR NR No
Yumoto
et al. [92]
No 12% No Yes Yes NR NR NR NR
Yumoto
et al. [93]
No 3% No Yes Yes NR NR NR NR
Papers with mortality as part of a composite endpoint are marked with a “≠”; in those cases, the data are reported for overall complications in which mortality is
included unless otherwise stated
NR not reported
1The cut-off value established for the prediction of postoperative LF is also used for the outcome mortality
2No patients in the interventional group died postoperatively, but in the 88 patients in the prior study by Chapelle et al. the mortality rate was 6%, also reported
in the table above
3Two patients died due to LF during the hospital stay. The NMT uptake values are reported for these two patients
4In the overall population including the cohort from 2000 to 2015 and the cohort from 2016 to 2019
5Comparison of outcomes in the cohort from 2000 to 2015 to those in the cohort from 2016 to 2019 applying different cut-off values for the function of the FLR
6Cut-off value, diagnostic characteristics, or mortality vs. no mortality for overall complications or poor outcome, but separate uptake values reported for patients
who died postoperatively
7They perform a log-rank test to compare survival rates in patients with liver uptake function above and below a certain level
8Cut-off value for postoperative LF
9AUC value only investigated for patients developing LF-related mortality (16%)
10Only in 98 patients who underwent hemi-hepatectomy did the authors evaluate mortality and LF. Therefore, the mortality event rate was 2/98 (2%)
11Postoperative clinical outcomes were only reported in the seven patients who underwent ALPPS. One of the seven patients died due to LF postoperatively
125-year overall mortality rate based on the reported 5-year overall survival rates of 55.2% in one group (n = 24) and 77.3% in another group (n = 259)
135-year overall mortality rate based on the reported 5-year overall survival rate of 82%. The 3-year tumor-free survival rate was 41%
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mortality as part of a composite endpoint) compared nu-
clear medicine results in patients with fatal versus non-
fatal outcomes. All studies found significant differences
in the nuclear medicine investigation results between pa-
tients with a fatal outcome and those with a non-fatal
outcome. Two papers compared survival rates in pa-
tients with liver function uptake values above or below a
certain level (reported in the same column). Nishikawa
et al. [60] found a significant difference between survival
rates in patients above and below a certain cut-off,
whereas Yano et al. [89] did not. Moreover, Rassam
et al. [67] did not find a significant association between
90-day mortality and the preoperative FLR function or
uptake rate of [99mTc]Tc-mebrofenin. Four papers retro-
spectively assessed the diagnostic test accuracy of the
cut-off determined based on the observations from their
study. Satoh et al. [68] analyzed the diagnostic character-
istics of the cut-off value in regard to predicting overall
complications in which mortality was included, whereas
Dinant et al. [24] and Nishiyama et al. [61] analyzed the
diagnostic characteristics of the cut-off value for the pre-
diction of LF-related mortality. The positive predictive
values were modest (50 to 71%), whereas the negative
predictive values were excellent (98 to 100%). Dinant
et al. [24] reported a sensitivity of 75% and specificity of
93% for predicting LF-related mortality. Olthof et al.
[65] found that the FLR function had an AUC of 0.70
for the prediction of liver failure-related mortality.
Six papers assessed the predictive value of the pre-
operative nuclear medicine test for postoperative mortal-
ity or a composite outcome in univariate and/or
multivariate regression analysis. Dinant et al. [24] found
that future remnant (FR) uptake determined by
[99mTc]Tc-mebrofenin liver imaging had significant pre-
dictive value for LF-related mortality but not all-cause
mortality in univariate analysis but not multivariate ana-
lysis. Hayashi et al. [28] showed that the FR function de-
termined from [99mTc]Tc-GSA imaging was a significant
predictor of postoperative mortality (odds ratio (OR) 8.8,
p = 0.008) in univariate analysis; no multivariate analysis
was performed. Kim et al. [39] found LHL15 to be a sig-
nificant predictor of overall complications, including
mortality, in multivariate analysis. Nishikawa et al. [60]
found the GSA index to be a significant predictor of
recurrence-free survival and overall survival in univariate
analysis and documented a significant predictive value of
the GSA index for recurrence-free survival in multivari-
ate cox regression analysis (hazard ratio (HR) 2.4, p <
0.001). However, Yano et al. [89] found that the GSA-
Rmax parameters were not associated with overall sur-
vival or tumor-free survival in multivariate cox regres-
sion analysis, and Yamao et al. [87] did not find a
significant association between LHL15 and overall sur-
vival in univariate cox regression analysis. Several other
studies claimed to document the predictive value of the
imaging tests evaluated, but the findings were not sup-
ported by statistical analyses.
Prediction of postoperative LF
Fifty-two studies reported on LF alone or as part of a
composite outcome (Table 3). Fifty (96%) of the trials in-
volved major surgery (entirely or partly). Among the
forty-four studies reporting on the definition of postop-
erative LF, the definition varied considerably (data not
shown). The postprocedural LF rate ranged from 0 to
86% (Table 4). Most trials (n = 35) were performed with
[99mTc]Tc-GSA, of which more than 25 different mea-
sures of liver function were applied (data no shown).
Twenty-one studies analyzed a predetermined cut-off
value, and nine studies did not report a cut-off value.
The remaining studies established a post hoc (data-
driven) cut-off value, and some reported both.
A large number of trials (n = 35) provided detailed
diagnostic or predictive data (Table 4). Twenty-six trials
compared the results of radionuclide imaging in patients
with or without liver failure for one or more imaging
variables. Most trials showed significant differences
among patients with and without liver failure for at least
one of the liver function parameters. Sixteen studies ana-
lyzed the diagnostic characteristics of the cut-off values
in predicting postoperative LF or overall complications.
In general, the sensitivity and specificity of the cut-off
values varied considerably from 50 to 100% and from 32
to 98%, respectively. The positive predictive values of the
cut-offs varied considerably as well (7 to 92%), whereas
the negative predictive values were consistently high (82
to 100%).
Twenty trials analyzed the predictive value of the nu-
clear medicine test in predicting postoperative LF or a
composite outcome including LF in univariate and/or
multivariate regression analyses, and some trials pre-
sented up to six variables. All studies showed significant
outcome in univariate regression analysis with at least
one nuclear medicine variable. Multivariate regression
analyses were performed in eighteen trials, fifteen of
which showed that a nuclear medicine liver function test
was a significant independent predictor of postoperative
LF (Table 4). Twelve of these trials presented the pre-
dictive impact with an OR or HR. Eleven of these studies
tested other variables as well, and only six of these stud-
ies [21, 22, 36, 57, 64, 65] found that other variables
(e.g., operation time, extent of hepatectomy, blood loss
volume, and aspartate aminotransferase to platelet ratio
index) had significant predictive value for predicting LF.
Historical comparisons
Five studies reported historical comparisons on the out-
come rate of LF and mortality in the period before and
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Table 3 Overview of the studies reporting on the correlation between a preoperative nuclear imaging examination and the
postoperative outcome liver failure
Author Liver
failure
defined
LF
event
rate
Preset
cut-off
value
studied
Post hoc
cut-off value
established
Only
descriptive
analysis
Liver failure vs.
no liver failure
comparison
Key diagnostic
characteristics
reported
Cut-off value
predictive in
univariate regression
analysis
Cut-off value
predictive in
multivariate
regression analysis
Cieslak et al.
[16]
Yes 2% Yes No Yes NR NR NR NR
Cieslak et al.
≠ [17]
No 11%1 Yes No2 Yes NR NR NR NR
Chapelle
et al. [19]
Yes 14% No Yes No Yes Yes Yes Yes
Chapelle
et al. [20]
Yes 1%3 Yes No Yes NR NR NR NR
Chapelle
et al. [21]
Yes 15% Yes No No Yes Yes NR Yes
Chiba et al.
[18]
Yes 6%4 Yes No No NR NR Yes Yes
Cho et al.
[22]
Yes 5% No Yes No Yes Yes Yes Yes
de Graaf
et al. [10]
Yes 16% No Yes No Yes Yes NR NR
Dinant et al.
[24]
Yes 13% No Yes No Yes Yes Yes Yes
Franken
et al. [25]
Yes 15%5 Yes No Yes6 NR NR NR NR
Guiu et al.
[27]
Yes 0% Yes No Yes NR NR NR NR
Hayashi
et al. [28]
Yes 8% Yes No No NR NR Yes NR
Hino et al.
≠ [29]7
Yes 4% No Yes Yes NR NR NR NR
Hirai et al.
[30]
Yes 23% No Yes No Yes Yes NR NR
Hwang
et al. ≠ [31]
No 9% No No No Yes NR NR NR
Kaibori et al.
[34]
Yes 8% No Yes No Yes Yes Yes Yes
Kamohara
et al. ≠ [35]
Yes NR
(30%
overall)
Yes No Yes NR NR NR NR
Kato et al. ≠
[36]
Yes 33%8 No Yes No Yes Yes NR Yes
Katsuramaki
et al. ≠ [37]7
Yes 3% No Yes Yes NR NR NR NR
Kawamura
et al. [38]
No 0% No No Yes NR NR NR NR
Kim et al. ≠
[39]
No 10% No Yes No Yes NR NR Yes
Kokudo
et al. [40]
Yes9 13% No Yes No Yes NR NR Yes
Kwon et al.
[45]
Yes 5% No Yes Yes NR NR NR NR
Mao et al.
[48]
Yes10 13% Yes Yes No NR Yes NR NR
Mitsumori
et al. [49]
No11 10% Yes No Yes NR NR NR NR
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Table 3 Overview of the studies reporting on the correlation between a preoperative nuclear imaging examination and the
postoperative outcome liver failure (Continued)
Author Liver
failure
defined
LF
event
rate
Preset
cut-off
value
studied
Post hoc
cut-off value
established
Only
descriptive
analysis
Liver failure vs.
no liver failure
comparison
Key diagnostic
characteristics
reported
Cut-off value
predictive in
univariate regression
analysis
Cut-off value
predictive in
multivariate
regression analysis
Nakamura
et al. [50]
Yes 17% No Yes No Yes NR NR Yes
Nakano
et al. ≠ [51]
Yes 6% Yes No No Yes NR NR No
Nanashima
et al. ≠ [54]7
Yes 6% No Yes No Yes NR NR NR
Nanashima
et al. ≠ [55]
Yes 6% No Yes No Yes NR NR No
Nanashima
et al. ≠ [56]
Yes 8% Yes (later
group)
Yes (earlier
group)
No Yes NR Yes No
Nanashima
et al. ≠ [57]
Yes 5% No Yes No Yes NR NR Yes (LF only)
Nanashima
et al. [58]
No 4% Yes No Yes NR NR NR NR
Nanashima
et al. [59]
Yes 1% No No No Yes NR NR NR
Nitta et al.
[62]
Yes 18% Yes Yes No Yes Yes NR Yes
Okabayashi
et al. [63]
Yes 10%12 Yes No Yes NR NR NR NR
Okabe et al.
[64]
Yes PLD
7%
LF 2%
No Yes (PLD) No Yes (PLD) Yes (PLD) NR Yes (PLD)
Olthof et al.
[65]
Yes 23% Yes Yes No Yes Yes Yes Yes
Rassam
et al. ≠[67]7
Yes 10%
(LF
only)
Yes No No Yes NR NR NR
Satoh et al.
≠ [68]7
Yes 9% No Yes No NR Yes NR NR
Serenari
et al. [69]
Yes 25%13 No Yes No Yes Yes NR NR
Serenari
et al. [70]
Yes 33% No No No Yes NR NR NR
Sugai et al.
≠ [73]
No 18% No No No Yes NR NR NR
Sumiyoshi
et al. [74]
Yes 7%14 Yes No No Yes NR NR NR
Sumiyoshi
et al. [75]
Yes 0% Yes No Yes NR NR NR NR
Tanaka et al.
[79]
Yes 41%15 Yes No No NR NR Yes NR
Tanoue
et al. [81]
Yes 15% No No16 No Yes NR NR NR
Truant et al.
[82]
Yes 80%17 No No Yes NR NR NR NR
Truant et al.
[83]
Yes 86%18 No No Yes NR NR NR NR
Yano et al.
[88]
Yes 21% No No16 No Yes NR NR NR
Yoshida Yes 6% No Yes No Yes Yes NR Yes
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after implementation of nuclear imaging as a preopera-
tive examination in patients undergoing liver surgery
[16, 20, 25, 56, 58]. Overall, the historical comparisons
involving [99mTc]Tc-mebrofenin found that implementa-
tion of nuclear imaging in the preoperative assessment
resulted in lower mortality and liver failure rates [16, 20,
25], whereas the historical comparisons on the use of
[99mTc]Tc-GSA did not result in a significant decrease
in the number of liver failure cases in the period after
implementation of [99mTc]Tc-GSA liver scintigraphy
[56, 58].
Discussion
To the best of our knowledge, this is the first systematic
review investigating the value of preprocedural nuclear
imaging examinations for the prediction of postproce-
dural mortality and LF in patients undergoing localized,
liver-directed interventions. This review demonstrated
great technical heterogeneity, e.g., in terms of tracers,
nuclear imaging uptake calculations, and outcome defi-
nitions. Most trials were retrospective and explored test-
derived cut-off values rather than evaluating the clinical
validity of predetermined variables and cut-off values.
However, a few studies investigated predetermined cut-
off values and confirmed the clinical utility of these for
the preoperative nuclear imaging examination both in
terms of producing low LF and mortality rates. In
addition, a notable number of trials reported significant
predictive values of the nuclear medicine imaging test in
multivariate analyses for the prediction of LF, which fa-
vors further efforts to identify the clinical utility of these
tests in a prospective setting.
The most promising and well-investigated nuclear
medicine imaging tracers for the prediction of postoper-
ative clinical outcome were [99mTc]Tc-GSA and
[99mTc]Tc-mebrofenin. Despite the fact that a large pro-
portion of these trials showed interesting diagnostic
properties and excellent predictive values, the method-
ology was not optimal in most cases. The definitions of
liver failure and mortality differed across the studies
without consensus on predefined, clinically relevant liver
failure and mortality definitions. This may ultimately
affect the outcome of the individual analyses and com-
plicate the ability to properly compare the tracers in the
studies in terms of their predictive value. Furthermore,
the majority of the studies were retrospective and had
an exploratory approach, and the diagnostic properties
of the nuclear imaging techniques were defined based
on the actual observations. A few papers applied a pre-
determined cut-off value in a prospective setting and
Table 3 Overview of the studies reporting on the correlation between a preoperative nuclear imaging examination and the
postoperative outcome liver failure (Continued)
Author Liver
failure
defined
LF
event
rate
Preset
cut-off
value
studied
Post hoc
cut-off value
established
Only
descriptive
analysis
Liver failure vs.
no liver failure
comparison
Key diagnostic
characteristics
reported
Cut-off value
predictive in
univariate regression
analysis
Cut-off value
predictive in
multivariate
regression analysis
et al. [90]
Yumoto
et al. [92]
No 19% No Yes Yes NR NR NR NR
Yumoto
et al. [93]
Yes9 17% No Yes No Yes Yes NR NR
Papers with liver failure as part of a composite endpoint are marked with a “≠”; in those cases, the data are reported for overall complications in which liver
failure is included unless otherwise stated
LF liver failure, PLD postoperative liver dysfunction
1Including three patients who died due to LF, but they only looked at the NMT in regard to developing LF postoperatively
2Not for the prediction of LF, but they establish a cut-off for the prediction of reaching a sufficient function of the FLR after PVE
31% of patients in the interventional group developed LF postoperatively, but in the 88 patients in the prior study by Chapelle et al., the liver failure rate was
14%, also reported in the table above
4Including two patients who died due to LF. Their primary endpoint was LF, but they also provided uptake values for the patients who died due to LF, also
reported in mortality table
5In the overall population including the cohort from 2000 to 2015 and the cohort from 2016 to 2019
6Comparison of outcomes in the cohort from 2000 to 2015 to those in the cohort from 2016 to 2019 applying different cut-off values for the function of the FLR
7Cut-off value, diagnostic characteristics, predictive value, or LF vs. no LF for overall complications or poor outcome, but separate uptake values for patients who
developed LF postoperatively
8Including 3 patients who died due to postoperative LF
9Signs of postoperative LF
10A Child Score > 9 is considered a high risk for developing LF
11Specifically described as hepatic insufficiency not LF
12Meeting the criteria for LF based on at least one of three definitions
13Including one patient who developed LF after stage 1 of the ALPPS procedure, and the other four patients developed LF after stage 2 of the ALPPS procedure
14LF-related Clavien-Dindo grade III complication
15Only in 98 patients who underwent hemi-hepatectomy did the authors evaluate mortality and LF. Therefore, the liver failure event rate was 40/98 (41%)
16Not for the prediction of LF, but they establish a cut-off for the prediction of postoperative long-term ascites
17Including one patient who developed LF and died postoperatively
18Postoperative clinical outcomes were only reported in the seven patients who underwent ALPPS. Six of the seven patients developed LF, five after stage 2 of
the ALPPS procedure and one postoperatively who also died. The other five recovered postoperatively
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investigated outcomes among patients with uptake
values above or below that cut-off. Thus, there were only
a few clinical utility studies. However, the studies apply-
ing a predetermined cut-off value in a prospective set-
ting validated the cut-off and proved that the cut-off
value was able to safely determine which patients could
undergo hepatic resection with resulting low mortality
and LF rates [20, 63], thereby underscoring the import-
ance of preoperative nuclear imaging in patients under-
going liver resection. A few studies investigated other
tracers; the limited number of data makes it difficult to
identify advantages or disadvantages over [99mTc]Tc-
GSA and [99mTc]Tc-mebrofenin.
The major differences between [99mTc]Tc-GSA and
[99mTc]Tc-mebrofenin exists in the uptake and excretion
of these tracers. The uptake of [99mTc]Tc-GSA follows
receptor-mediated endocytosis by attachment to asialo-
glycoprotein receptors on the functioning hepatocytes.
The tracer is then transferred to the lysosomes for deg-
radation [94]. As the only uptake site for [99mTc]Tc-
GSA is in the liver, imaging with [99mTc]Tc-GSA offers
a good representation of the functioning hepatocytes. In
comparison, [99mTc]Tc-mebrofenin is transported to the
liver predominantly bound to albumin after which it is
taken up by the functioning hepatocytes and excreted
unmetabolized into the bile system. As a result, imaging
with [99mTc]Tc-mebrofenin offers visualization of the
liver’s uptake and excretion function including the bil-
iary tract system [94]. However, imaging with
[99mTc]Tc-mebrofenin can be affected by high blood
bilirubin levels as both substrates compete for the same
uptake transporter on the hepatocytes [94]. Both im-
aging methods are capable of estimating both the global
and regional liver function with the use of SPECT. No
head-to-head comparative studies of the two tracers in
the same population were identified.
Hepatobiliary scintigraphy has shown a promising
value in the preoperative assessment of patients under-
going liver resection, and it has been utilized by several
nuclear medicine departments worldwide over the last
decade. Still, there are no widely accepted international
guidelines that recommend the use of nuclear medicine
imaging to determine the resectability of patients prior
to undergoing a procedure with the purpose of removing
diseased liver tissue. CT volumetry, however, is well
established for the preoperative estimation of FLR vol-
ume prior to liver surgery and is the present gold stand-
ard to determine resectability in patients undergoing
liver resection. Preoperative CT volumetry cut-off values
for a safe liver resection have been established on the
basis of several well-designed studies [95–101]. It is gen-
erally accepted that approximately 75–80% of the total
liver volume can be removed safely without postopera-
tive complications, leaving a FLR of approximately 20–
25% if the liver morphology and liver function are nor-
mal [95–101]. If the normal liver has been subjected to
chemotherapy recently, a FLR volume of 30% is neces-
sary, and in patients with cirrhosis or hepatitis, the FLR
volume needs to be at least 40%, depending on the total
liver function measured by a variety of tests and scores
[99–101].
CT volumetry is, however, an indirect measure of liver
function due to the heterogeneously distributed liver tis-
sue, especially in patients with parenchymal liver disease.
Therefore, using CT volumetry as a preoperative meas-
ure of the FLR requires knowledge of the quality of the
liver parenchyma [11] as reflected in the different cut-off
values for the various liver conditions. In addition, in
using CT volumetry as the preoperative assessment of
the FLR, some patients are at risk of being excluded
from surgery with curative intent due to a small FLR
volume, even if their actual FLR function is sufficient.
Other patients with sufficient FLR volume are at risk of
developing postoperative liver failure due to insufficient
FLR function. To avoid these problems, a more direct
evaluation of FLR function is needed, and nuclear im-
aging seems to be the most promising approach. Fur-
thermore, with the use of nuclear imaging as a
preoperative measure of the FLR function, one cut-off
level for a safe liver resection might suffice for all pa-
tients regardless of the underlying liver function [10, 11].
Therefore, it would be advantageous for clinicians to es-
timate the function of the FLR and thus the postproce-
dural clinical course of the patients while taking into
account the underlying liver disease.
For the nuclear imaging techniques to be included in
the diagnostic assessment of patients undergoing liver-
directed treatments, clinicians need evidence-based cut-
off values for the nuclear imaging liver functional assess-
ment based on a validated and simple liver function up-
take calculation. Most cut-off values shown in this
systematic review were post hoc, data-driven values, not
prospective assessments of a fixed cut-off value. It was
evident that nuclear imaging techniques play a promis-
ing role in the preprocedural work-up of patients under-
going liver-directed treatments, especially for the
prediction of postoperative liver failure. However, the
liver failure and mortality predictions are influenced by
the different and inconsistent liver failure and mortality
definitions. The abundant heterogeneity in nuclear im-
aging techniques, acquisition methods, and outcome def-
initions complicate the ability to establish evidence-
based guidelines for the preprocedural work-up of pa-
tients undergoing liver-directed treatment. External val-
idation and comparison of the results across the
different studies require procedural standardization,
both of technical performance and outcome. Rassam
et al. have described practical guidelines on how to use
Espersen et al. EJNMMI Research          (2020) 10:101 Page 18 of 22
[99mTc]Tc-mebrofenin hepatobiliary scintigraphy [102].
Most papers investigated both major and minor surgery
in the same study and established a joint cut-off for a
safe liver resection irrespective of the surgery type. How-
ever, the extent of liver surgery may affect the FLR cut-
off needed for a safe surgery and a favorable postopera-
tive outcome. Therefore, future studies should distin-
guish between major and minor surgery in their
prediction models and cut-off establishments. It remains
unclear if the same cut-off can be used across different
type of interventions.
Due to the interesting data generated with the tracers
[99mTc]Tc-GSA and [99mTc]Tc-mebrofenin, prospective
trials with predefined and clinically relevant definitions
of mortality and liver failure are warranted. However,
[99mTc]Tc-GSA is not yet commercially available outside
of Japan and there are currently no head-to-head studies
comparing this tracer with [99mTc]Tc-mebrofenin. The
two tracers should be directly compared in prospective,
multicenter studies in patients undergoing major liver
surgery using predefined definitions of liver failure and
mortality; the predictive findings should be compared to
the gold standard of CT volumetry. This would hope-
fully lead to an extraction of clinically relevant cut-off
levels of the nuclear imaging techniques for a safe
hepatectomy.
This up-to-date systematic review covered four de-
cades of research published in two major medical data-
bases, employed extensive and detailed research strings,
and had two investigators throughout the review and
data extraction process. The authors consider this sys-
tematic review to encompass the first synthesized evi-
dence on this clinically relevant topic.
Some groups published several, similarly appearing pa-
pers; some groups published papers with increasing
number of subjects over time. We did not contact indi-
vidual authors to investigate any overlapping data among
papers from the same institution. This may cause a po-
tential bias of duplicate or overlapping data if authors
did not comply with established guidelines on the ethics
of publishing.
Conclusion
In conclusion, more than 80 trials have been published
on preoperative nuclear medicine methods, predomin-
antly [99mTc]Tc-GSA and [99mTc]Tc-mebrofenin, to pre-
dict clinical outcomes after the liver-directed treatment
of non-systemic liver diseases. Even though we identified
evidence of benefit for preoperative nuclear medicine as-
sessment across various liver diseases, the data were very
heterogeneous concerning the methodology for liver
function uptake calculations and dissimilar outcome def-
initions of LF and mortality. The general impression was
that this area of research is short of confirmatory and
consistent evidence to determine the patient-relevant
benefit of the preoperative assessment of the postopera-
tive FLR with nuclear medicine tests. We encourage the
nuclear medicine society in collaboration with hepato-
biliary surgeons to support prospective, multi-national
clinical efficacy trials documenting that adding a pre-
operative nuclear medicine test benefits patients in com-
parison to the standard of care for preoperative
investigations using CT volumetry.
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